Real-time Quotes | Nasdaq Last Sale

After Hours: 134.49 0 0.00% 16:53 11/23 EST
Corp Actions
Sarepta Therapeutics Named One of The Boston Globes Top Places to Work 2020
\-- Sarepta is honored to be recognized for offering a range of benefits and work-life resources to employees and supporting the local community \-- \-- Rankings based on confidential survey information submitted by employees to independent research company \--CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has been named one of The Boston Globe’s Top Places to Work in 2020 in the large company category.The Boston Globe’s 2020 list recognizes 150 companies and organizations in Massachusetts based on surveys completed by their employees about the workplace, including 40 in the large company category. The survey measured opinions about company direction, execution, connection, management, work, pay and benefits, and engagement. Companies also provided supplemental information about responses to the global pandemic and changes implemented in how teams work.“This recognition reflects the quality of the Sarepta employees, who together have built a positive culture, navigated a challenging environment this year and, both at facilities and from home, remained focused on our daily race to save lives stolen or impacted by rare disease,” said Doug Ingram, president and CEO, Sarepta. “It is a testament to the resilience, tenacity and commitment of those who work at Sarepta.”Sarepta is committed to engineering precision genetic medicine to reclaim futures otherwise impacted or cut short by ushering in a new era of drug development, with the goal of shortening the time from lab to patient. The Company is building among the world’s largest gene therapy manufacturing capacity, and rethinking access and reimbursement models for revolutionary new treatments. Sarepta’s purpose-driven culture, where patient-focus is central to the values that shape how work is done, was resoundingly echoed by its people as a key attribute that contributed to its top ranking. Additionally, Sarepta fosters an environment that encourages its people to bring their whole selves to work and share ideas that support the entire workforce and the patient community it serves.As the Company adjusted during the pandemic, several initiatives and new benefits were implemented as a result of employee feedback: * Employees rethought how clinical trials were conducted and how to make it easier for patients to participate. * The Company launched multiple caregiving benefits for employees managing dependent care, including tutoring support and an employee-led babysitting exchange program to help parents manage working from home and address childcare needs. * Virtual health and wellness seminars focused on coping under chronic stress and during transitions, and employees received virtual care packages. * Employee Resource Groups addressed diversity, equity and inclusion by bringing together diverse groups to support organization and personal growth. * Employees remain connected to the communities in which they work and live through volunteer opportunities and Company sponsorship of non-profit organizations. At Sarepta, a vision for the possibilities of pioneering science to redefine the future of medicine, and advance treatment options for patients, is shared by all. Individuals who are inspired by the opportunity to toss aside convention and break down barriers to radically change the future of medicine are encouraged to explore employment opportunities at Sarepta Therapeutics At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visit or follow us on Twitter, LinkedIn, Instagram and Facebook.Source: Sarepta Therapeutics, Inc.Media and Investors: Sarepta Therapeutics, Inc. Investors: Ian Estepan, 617-274-4052, Media: Tracy Sorrentino, 617-301-8566,
GlobeNewswire · 3d ago
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Last week, you might have seen that Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its third-quarter result to the...
Simply Wall St. · 11/09 14:30
Biogen's Aducanumab Fails To Win FDA Panel Backing
Biogen Inc (NASDAQ: BIIB) failed to win the backing of the FDA panel which reviewed the BLA for its controversial Alzheimer's drug aducanumab, an antibody which targets amyloid-beta.
Benzinga · 11/06 22:04
Credit Suisse Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $162
Credit Suisse maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $167 to $162.
Benzinga · 11/06 17:38
Sarepta Therapeutics Q3 EPS $(1.42) Beats $(1.71) Estimate, Sales $143.92M Beat $137.43M Estimate
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(1.42) per share which beat the analyst consensus estimate of $(1.71) by 16.96 percent. This is a 24.56 percent decrease over losses of $(1.14) per share
Benzinga · 11/05 22:15
This Biotech's Gene Therapy Sales Grew 23% But That Wasn't Enough
Investor's Business Daily · 11/05 21:59
Sarepta Exondys 51 and Vyondys 53 sales up 23% in Q3
Sarepta Therapeutics (SRPT) Q3 results:Revenues: $143.9M (+45.4%); product sales: $121.4M (+22.6%); collaboration revenue: $22.5M (primarily from Roche).Net loss: ($196.5M) (-55.6%); loss/share: ($2.50) (-47.1%).Quick assets: $1,816,1M (+61.5%).Q4 consensus: loss/share of ($1.78)
Seekingalpha · 11/05 21:33
Sarepta Therapeutics EPS misses by $0.02, beats on revenue
Sarepta Therapeutics (SRPT): Q3 Non-GAAP EPS of -$1.42 misses by $0.02; GAAP EPS of -$2.50 misses by $0.76.Revenue of $143.92M (+45.3% Y/Y) beats by $10.23M.The company announced collaboration with University
Seekingalpha · 11/05 21:26
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRPT. Analyze the recent business situations of Sarepta through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 25 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SRPT stock price target is 189.48 with a high estimate of 217.00 and a low estimate of 140.00.
Institutional Holdings
Institutions: 606
Institutional Holdings: 76.16M
% Owned: 96.51%
Shares Outstanding: 78.91M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Biotechnology & Medical Research
Pharmaceuticals & Medical Research
Key Executives
Chairman/Independent Director
M. Kathleen Behrens
President/Chief Executive Officer/Director
Douglas Ingram
Chief Financial Officer/Chief Accounting Officer
Joseph Bratica
Executive Vice President/General Counsel/Secretary
David Howton
Executive Vice President
William Ciambrone
Executive Vice President
Alexander Cumbo
Executive Vice President
Gilmore O'Neill
Independent Director
Richard Barry
Independent Director
Mary Gray
Independent Director
John Martin
Independent Director
Claude Nicaise
Independent Director
Hans Wigzell
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SRPT
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.
Hot Stocks

Webull offers kinds of Sarepta Therapeutics Inc stock information, including NASDAQ:SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.